278 related articles for article (PubMed ID: 12654190)
61. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
Jang JY; Park YC; Song YS; Lee SE; Hwang DW; Lim CS; Lee HE; Kim WH; Kim SW
J Hepatobiliary Pancreat Surg; 2009; 16(5):668-74. PubMed ID: 19412570
[TBL] [Abstract][Full Text] [Related]
62. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer.
Wu D; Qian JM; Deng RX; Jiang WJ; Chen YJ; Liu XH; Lu XH
Chin J Dig Dis; 2006; 7(2):117-20. PubMed ID: 16643340
[TBL] [Abstract][Full Text] [Related]
63. Significance of K-ras mutation and CEA level in pancreatic juice in the diagnosis of pancreatic cancer.
Futakawa N; Kimura W; Yamagata S; Zhao B; Ilsoo H; Inoue T; Sata N; Kawaguchi Y; Kubota Y; Muto T
J Hepatobiliary Pancreat Surg; 2000; 7(1):63-71. PubMed ID: 10982594
[TBL] [Abstract][Full Text] [Related]
64. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases.
Ozkan H; Akar T; Köklü S; Coban S
Pancreatology; 2006; 6(4):268-72. PubMed ID: 16636598
[TBL] [Abstract][Full Text] [Related]
65. Diagnosis of pancreatic cancer by cytology and measurement of oncogene and tumor markers in pure pancreatic juice aspirated by endoscopy.
Nakaizumi A; Uehara H; Takenaka A; Uedo N; Sakai N; Yano H; Ohigashi H; Ishikawa O; Ishiguro S; Sugano K; Tatsuta M
Hepatogastroenterology; 1999; 46(25):31-7. PubMed ID: 10228761
[TBL] [Abstract][Full Text] [Related]
66. Noninvasive detection through REMS-PCR technique of K-ras mutations in stool DNA of patients with colorectal cancer.
Mixich F; Ioana M; Voinea F; Săftoiu A; Ciurea T
J Gastrointestin Liver Dis; 2007 Mar; 16(1):5-10. PubMed ID: 17410282
[TBL] [Abstract][Full Text] [Related]
67. Serum CA19-9 determination in the management of pancreatic cancer.
van den Bosch RP; van Eijck CH; Mulder PG; Jeekel J
Hepatogastroenterology; 1996; 43(9):710-3. PubMed ID: 8799418
[TBL] [Abstract][Full Text] [Related]
68. Detection of K-ras point mutation at codon 12 in pancreatic diseases: a study in a Brazilian casuistic.
Kubrusly MS; Cunha JE; Bacchella T; Abdo EE; Jukemura J; Penteado S; Morioka CY; de Souza LJ; Machado MC
JOP; 2002 Sep; 3(5):144-51. PubMed ID: 12221329
[TBL] [Abstract][Full Text] [Related]
69. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
Bloomston M; Bekaii-Saab TS; Kosuri K; Cowgill SM; Melvin WS; Ellison EC; Muscarella P
Pancreas; 2006 Oct; 33(3):246-9. PubMed ID: 17003645
[TBL] [Abstract][Full Text] [Related]
70. Persistence of K-ras mutations in plasma after colorectal tumor resection.
Lindforss U; Zetterquist H; Papadogiannakis N; Olivecrona H
Anticancer Res; 2005; 25(1B):657-61. PubMed ID: 15816642
[TBL] [Abstract][Full Text] [Related]
71. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice.
Mann DV; Edwards R; Ho S; Lau WY; Glazer G
Eur J Surg Oncol; 2000 Aug; 26(5):474-9. PubMed ID: 11016469
[TBL] [Abstract][Full Text] [Related]
72. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer.
Singh MK; Chetri K; Pandey UB; Kapoor VK; Mittal B; Choudhuri G
J Gastroenterol Hepatol; 2004 Aug; 19(8):916-21. PubMed ID: 15242496
[TBL] [Abstract][Full Text] [Related]
73. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma.
Liao WC; Wu MS; Wang HP; Tien YW; Lin JT
Pancreas; 2009 May; 38(4):422-6. PubMed ID: 19214136
[TBL] [Abstract][Full Text] [Related]
74. [Value of serum CA 19-9 determination in the diagnosis of pancreatic carcinoma].
Pei DP
Zhonghua Wai Ke Za Zhi; 1990 Oct; 28(10):625-7, 638-9. PubMed ID: 2086060
[TBL] [Abstract][Full Text] [Related]
75. [K-ras mutation in pancreatic juice from patients with pancreatic carcinoma].
Gong X; Chen Y; Chen Y; Lu X
Zhonghua Nei Ke Za Zhi; 1999 Oct; 38(10):673-6. PubMed ID: 11798705
[TBL] [Abstract][Full Text] [Related]
76. Detection of mutated c-Ki-ras in the bile of patients with pancreatic cancer.
Abbruzzese JL; Evans DB; Raijman I; Larry L; King T; Leach SD; Frazier ML
Anticancer Res; 1997; 17(2A):795-801. PubMed ID: 9137410
[TBL] [Abstract][Full Text] [Related]
77. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
Marrelli D; Caruso S; Pedrazzani C; Neri A; Fernandes E; Marini M; Pinto E; Roviello F
Am J Surg; 2009 Sep; 198(3):333-9. PubMed ID: 19375064
[TBL] [Abstract][Full Text] [Related]
78. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance.
Castells A; Puig P; Móra J; Boadas J; Boix L; Urgell E; Solé M; Capellà G; Lluís F; Fernández-Cruz L; Navarro S; Farré A
J Clin Oncol; 1999 Feb; 17(2):578-84. PubMed ID: 10080602
[TBL] [Abstract][Full Text] [Related]
79. [Detection and clinical study of serum tumor markers in patients with colorectal cancer].
Zhao XW; Jiang B; Han CZ; Jing JX
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):286-8. PubMed ID: 15996321
[TBL] [Abstract][Full Text] [Related]
80. [Restriction enzyme mismatch polymerase chain reaction in the demonstration of Ki-ras-oncogene mutation in carcinoma of the pancreas].
Heller T; Trautmann B; Zöller-Utz I; König HJ; Liebe S; Ell C; Löhr M
Dtsch Med Wochenschr; 1995 Jun; 120(23):826-30. PubMed ID: 7781523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
